Literature DB >> 6175159

Advanced catecholaminergic disturbances in the brain in a case of Wilson's disease.

P Nyberg, C G Gottfries, G Holmgren, S Persson, B E Roos, B Winblad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6175159     DOI： 10.1111/j.1600-0404.1982.tb03063.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


× No keyword cloud information.
  10 in total

1.  Improvement of cardiovascular autonomic dysfunction following anti-copper therapy in Wilson's disease.

Authors:  Kazushi Deguchi; Iwao Sasaki; Tetsuo Touge; Masago Tsukaguchi; Kazuyo Ikeda; Mieko Shimamura; Yoshiteru Urai; Seishiro Watanabe; Hiroaki Takeuchi; Shigeki Kuriyama
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

2.  Association of dopamine receptor gene polymorphisms with the clinical course of Wilson disease.

Authors:  T Litwin; G Gromadzka; J Samochowiec; A Grzywacz; A Członkowski; A Członkowska
Journal:  JIMD Rep       Date:  2012-07-06

Review 3.  Copper and the brain noradrenergic system.

Authors:  Svetlana Lutsenko; Clorissa Washington-Hughes; Martina Ralle; Katharina Schmidt
Journal:  J Biol Inorg Chem       Date:  2019-11-05       Impact factor: 3.358

4.  The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography.

Authors:  B J Snow; M Bhatt; W R Martin; D Li; D B Calne
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

5.  Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease.

Authors:  G Schlaug; H Hefter; B Nebeling; V Engelbrecht; P Weiss; G Stöcklin; R J Seitz
Journal:  J Neurol       Date:  1994-10       Impact factor: 4.849

6.  Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.

Authors:  B Jeon; J M Kim; J M Jeong; K M Kim; Y S Chang; D S Lee; M C Lee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

7.  Potential Role of Brain-Derived Neurotrophic Factor and Dopamine Receptor D2 Gene Variants as Modifiers for the Susceptibility and Clinical Course of Wilson's Disease.

Authors:  Shubhrajit Roy; Prosenjit Pal; Sampurna Ghosh; Sreyashi Bhattacharya; Shyamal Kumar Das; Prasanta Kumar Gangopadhyay; Ashish Bavdekar; Kunal Ray; Mainak Sengupta; Jharna Ray
Journal:  Neuromolecular Med       Date:  2018-07-10       Impact factor: 3.843

8.  Sleep in Wilson's disease: Questionnaire based study.

Authors:  Archana B Netto; Sanjib Sinha; Arun B Taly; Samhita Panda; Shivaji Rao
Journal:  Ann Indian Acad Neurol       Date:  2011-01       Impact factor: 1.383

9.  Autonomic Dysfunction in Wilson's Disease: A Comprehensive Evaluation during a 3-Year Follow Up.

Authors:  Kai Li; Charlotte Lindauer; Rocco Haase; Heinz Rüdiger; Heinz Reichmann; Ulrike Reuner; Tjalf Ziemssen
Journal:  Front Physiol       Date:  2017-10-10       Impact factor: 4.566

10.  Dysregulated Choline, Methionine, and Aromatic Amino Acid Metabolism in Patients with Wilson Disease: Exploratory Metabolomic Profiling and Implications for Hepatic and Neurologic Phenotypes.

Authors:  Tagreed A Mazi; Gaurav V Sarode; Anna Czlonkowska; Tomasz Litwin; Kyoungmi Kim; Noreene M Shibata; Valentina Medici
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.